Veeva Systems
Life sciences cloud platform providing CRM, Vault, and data solutions for pharma, biotech, and medical device companies. Industry-standard for clinical, regulatory, and commercial operations.
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 88/100, high switching costs, 124% NRR.
Growth appears healthy from +16% YoY revenue growth.
Forward P/E of 18.3x versus +16% growth gives a 1.1x multiple-to-growth read.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Retention and AI disruption risks are low; valuation is not flagged expensive.
Fundamentals from finnhub as of 2026-05-17; ownership confirmation is not available here.
Revenue growth helps show whether Veeva is still expanding before valuation debates take over.
Beginner valuation check
Data pending from FMP or Finnhub.
Negative price performance shows recent market sentiment, not a full investment thesis.
Forward P/E around 18.3x means investors pay about $18.3 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.
A P/E around 28.5x means investors pay about $28.5 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Veeva helps drug companies keep track of their medicines and the papers that prove they work. It's like a big organized filing cabinet in the cloud that doctors and scientists use to make sure everything is done right.
Life sciences cloud platform providing CRM, Vault, and data solutions for pharma, biotech, and medical device companies. Industry-standard for clinical, regulatory, and commercial operations.
Veeva Systems makes money through Veeva CRM (~$1.2B), Vault Clinical (~$1.5B), Vault Regulatory (~$600M), and Veeva Data Cloud (~$400M).
Industry-standard CRM and Vault platform for life sciences—pharma and biotech rarely switch once integrated with regulatory workflows
Veeva Systems can disappoint if execution, competition, valuation, or demand cycles weaken growth, margins, customer retention, or investor confidence.
Veeva Systems is like a business operating system for veeva crm: customers pay because replacing it can be disruptive.
You are basically betting that Veeva Systems can keep turning veeva crm into durable value while managing execution, competition, valuation, or demand cycles.
A 0-100 shortcut for how defensible the business looks in this company brief. Veeva Systems is scored at 88.
How painful it is for customers to leave. this company brief rates Veeva Systems as high.
Whether existing customers tend to spend more or less over time. The company brief model uses 124%.
The main pieces of the company here are Veeva CRM, Vault Clinical, Vault Regulatory, and Veeva Data Cloud.
Price divided by earnings. It is a quick valuation check, but it can mislead when earnings are temporarily high, low, or negative.
A quarterly filing that shows what many large institutional investors owned at quarter end.
The first four questions
Veeva’s life-sciences platform is deeply embedded in CRM, clinical, and regulatory workflows, and the company’s 124% net revenue retention points to continued expansion in Vault and data cloud modules.
The stock can come under pressure if Vault expansion slows, renewal/retention weakens, or investors decide the current valuation no longer fits the growth rate.
Net revenue retention (124%)
Next earnings date unavailable from configured sources.
Bull / Neutral / Bear
The business stays durable, but the market focuses on whether forward P/E is justified by continued growth rather than a faster re-rating.
Forward P/E around 18.3x remains balanced against roughly 16% revenue growth.
Veeva keeps adding Vault and data cloud modules on top of its entrenched CRM base, with high switching costs supporting ongoing expansion.
Net revenue retention stays near 124% or improves, while revenue growth remains positive.
The business stays durable, but the market focuses on whether forward P/E is justified by continued growth rather than a faster re-rating.
Forward P/E around 18.3x remains balanced against roughly 16% revenue growth.
Slower expansion, weaker retention, or a softer demand backdrop makes the market less willing to pay up for Veeva’s workflow moat.
Revenue growth or retention trends weaken, especially in Vault-led expansion.
Beginner checklist
Needs earnings calendar data from a provider.
Revenue growth helps show whether Veeva is still expanding before valuation debates take over.
Margin trend needs company financial statement data; do not infer it from price movement.
Forward P/E is the main valuation anchor available here, but it should be weighed against growth and retention.
No SEC-backed ownership rows are available for this ticker yet.
Needs insider transaction data from a provider.
For Veeva, NRR is a useful operating KPI because Vault expansion and cross-sell are central to the story.
Veeva Systems is exposure to veeva crm with high switching costs and 124% net revenue retention.
Industry-standard CRM and Vault platform for life sciences—pharma and biotech rarely switch once integrated with regulatory workflows
The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.
Use the simulator to walk through the workflows, systems, and data dependencies investors are effectively buying.
Business Lines
What's Inside
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- Industry-standard CRM and Vault platform for life sciences—pharma and biotech rarely switch once integrated with regulatory workflows
- Deep regulatory moat: Vault eTMF, regulatory submissions, and quality docs are FDA-validated and embedded in GxP processes
- Vault expansion driving land-and-expand: customers add Clinical, Regulatory, Quality, and Safety modules over time
- 124% NRR reflects strong upsell into Vault and data cloud; commercial CRM is mature but Vault has long runway
- AI disruption risk is low—regulated industries move slowly; Veeva's domain expertise and compliance posture are defensible
- High switching costs from data lock-in, validation burden, and integration with CROs, sites, and regulatory agencies